Pasar al contenido principal

MicroRNAs inmunoreguladores en diabetes tipo 1. Biomarcadores y dianas terapéuticas de autoinmunidad y recuperación de célula beta en la remisión parcial

PI22/00045

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes, miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Armengol, Maria Pilar
  • Alcalde-Herraiz, Marta|||0009-0002-4405-1814
  • Català, Martí|||0000-0003-3308-9905
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Sunye, Sergi
  • Valls, Aina|||0000-0002-0751-5029
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Vives Pi, Marta|||0000-0003-3735-0779
The partial remission (PR) phase of type 1 diabetes (T1D) is an underexplored period characterized by endogenous insulin production and downmodulated autoimmunity. To comprehend the mechanisms behind this transitory phase and develop precision medicine strategies, biomarker discovery and patient stratification are unmet needs. MicroRNAs (miRNAs) are small RNA molecules that negatively regulate gene expression and modulate several biological processes, functioning as biomarkers for many diseases. Here, we identify and validate a unique miRNA signature during PR in pediatric patients with T1D by employing small RNA sequencing and RT-qPCR. These miRNAs were mainly related to the immune system, metabolism, stress, and apoptosis pathways. The implication in autoimmunity of the most dysregulated miRNA, miR-30d-5p, was evaluated in vivo in the non-obese diabetic mouse. MiR-30d-5p inhibition resulted in increased regulatory T cell percentages in the pancreatic lymph nodes together with a higher expression of CD200. In the spleen, a decrease in PD-1 + T lymphocytes and reduced PDCD1 expression were observed. Moreover, miR-30d-5p inhibition led to an increased islet leukocytic infiltrate and changes in both effector and memory T lymphocytes. In conclusion, the miRNA signature found during PR shows new putative biomarkers and highlights the immunomodulatory role of miR-30d-5p, elucidating the processes driving this phase.